Manufacturing centre, Stevenage, UK

We are building a £55m large-scale GMP manufacturing centre in Stevenage to help bring cell and gene therapies to market in the UK and internationally. 

The Cell and Gene Therapy Catapult GMP manufacturing centre is designed to meet your needs and will included 12 segregated modules, each 100m2 grade B or C. The centre will provide centralised GM and support services.

Budget unveils £55m large-scale Cell Therapy Manufacturing Centre for the UK (March 2014)

In our 2013 survey of Good Manufacturing Practice, we identified manufacturing and supply chain as one of the barriers to the translation of research into commercially viable products.

The facility, due to open in 2017 will aim to de-risk capital by offering collaborators a low capital outlay from the beginning. It will provide acceleration of commercial scale production and offer certainty of manufacturing future. It will give you control of your manufacturing strategy and be MHRA licensed.

The centre will also provide the UK with the manufacturing facilities needed for later-stage cell and gene therapy clinical studies and commercialization:

  • 7,200m2 world-leading GMP manufacturing centre
  • Highly-skilled workforce
  • Cluster development
  • Excellent logistics infrastructure 

Located in Stevenage, the centre will have excellent supply chain infrastructure and is less than 24hrs from most major European cities:

Location of the GMP manufacturing centre

 

Building the GMP manufacturing centre: 

You can see how the construction is progressing from our live feed from the site:

Manufacturing centre live feed

 
 

The Cell Therapy Catapult cell and gene therapy manufacturing centre will be the world's first facility of its kind. I am very proud that it will be built in the UK. The UK is at the leading edge of the cell and gene therapy industry, with a disproportionate share of both world leading scientists and new developments in the field. It will also contribute to considerable additional inward investment to the UK. This has created an advantage upon which the country has to continue to capitalise. The centre will contribute to the development of a large scale industry in the UK and the development of a cell and gene therapy cluster that will deliver both health and wealth to the UK.

George Freeman, MP

Documents relating to the centre:

User Requirement Brief (June 2014)

Site Selection Process (June 2014)

Discover who we are